Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
NX-2127 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies.
SAN FRANCISCO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that its clinical-stage BTK degrader programs will be featured in two oral presentations and one poster presentation at the 64th American Society of Hematology Annual Meeting and Exposition being held December 10-13, 2022 in New Orleans, LA. The oral presentation by Dr. Anthony Mato of Memorial Sloan Kettering Cancer Center will include a clinical update on chronic lymphocytic leukemia patients from Nurix’s ongoing Phase 1 trial of NX-2127.
Oral Presentation Details:
Title: NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
Speaker: Anthony Mato, M.D., MSCE, Director of the Chronic Lymphocytic Leukemia (CLL) Program at Memorial Sloan Kettering Cancer Center
Presentation Time: 5:30 PM CT
Session Name: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Drugs in Development and COVID-19
Session Date and Time: Monday, December 12, 2022, 4:30 PM - 6:00 PM CT
Location: Ernest N. Morial Convention Center, 243-245
Publication Number: 965
Title: Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
Speaker: Omar Abdel-Wahab, M.D., Director of the Center for Hematologic Malignancies at Memorial Sloan Kettering Cancer Center
Presentation Time: 11:45 am CT
Session Name: 641. Chronic Lymphocytic Leukemias: Basic and Translational: Novel Therapies and Biomarkers
Session Date and Time: Monday, December 12, 2022, 10:30 AM - 12:00 PM CT
Location: Ernest N. Morial Convention Center, La Nouvelle Orleans Ballroom AB
Publication Number: 750
Poster Presentation Details:
Title: Bruton’s Tyrosine Kinase (BTK) degrader NX-2127 exhibits lethal activity and synergy with venetoclax and BET protein inhibitor against MCL cells sensitive or resistant to covalent BTK inhibitors
Authors: Warren Fiskus, Kaberi Das, Christopher Mill, Christine Birdwell, John Davis, Noor Alhamadani, Kevin Philip, May Tan, Robert Brown, Michael Green, and Kapil N. Bhalla
Session Name: 605. Molecular Pharmacology and Drug Resistance
Lymphoid Neoplasms: Poster II
Session Date and Time: Sunday, December 11, 2022, 6:00 PM - 8:00 PM CT
Location: Ernest N. Morial Convention Center, Hall D
Publication Number: 2663
About NX-2127
NX-2127 is a novel bifunctional molecule that degrades Bruton’s tyrosine kinase (BTK) and cereblon neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3). NX-2127 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. Additional information on the ongoing clinical trial can be accessed at www.clinicaltrials.gov (NCT04830137).
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Forward Looking Statement
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding Nurix’s current and prospective drug candidates and the planned timing for the provision of updates and findings from Nurix’s clinical trials. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) risks and uncertainties related to Nurix’s ability to advance its drug candidates, obtain regulatory approval of and ultimately commercialize its drug candidates; (ii) the timing and results of clinical trials; (iii) Nurix’s ability to fund development activities and achieve development goals; (iv) the impact of the COVID-19 pandemic and increasing financial market volatility and uncertainty on Nurix’s business, clinical trials, financial condition, liquidity and results of operations; (v) Nurix’s ability to protect its intellectual property and (vi) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2022, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.
Contacts:
Investors
Silinda Neou
Nurix Therapeutics
[email protected]
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
[email protected]
Media
Brett Whelan
LifeSci Communications
[email protected]
